Novartis pauses autoimmune cell therapy studies after deaths, WSJ reports

​Novartis ‌paused eight clinical ​trials ‌of an experimental ‌therapy targeting ‌autoimmune and neurological ⁠disorders ​in ⁠late August, after ⁠three ​patients died, the Wall ⁠Street ⁠Journal ​reported on ⁠Tuesday.